Novavax (NVAX)
(Delayed Data from NSDQ)
$15.12 USD
+2.01 (15.33%)
Updated Jul 15, 2024 03:57 PM ET
After-Market: $15.18 +0.06 (0.40%) 7:44 PM ET
2-Buy of 5 2
D Value D Growth C Momentum D VGM
Novavax (NVAX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$22.80 | $38.00 | $10.00 | 73.91% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Novavax comes to $22.80. The forecasts range from a low of $10.00 to a high of $38.00. The average price target represents an increase of 73.91% from the last closing price of $13.11.
Analyst Price Targets (5 )
Broker Rating
Novavax currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, three are Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/NVAX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 1 |
Sell | 0 | 0 | 0 | 0 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 1 |
ABR | 2.00 | 2.00 | 2.00 | 2.00 | 2.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/23/2024 | B. Riley Securities | Mayank Mamtani | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Brendan Smith | Hold | Hold |
3/1/2024 | H.C. Wainwright & Co. | Vernon Bernardino | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 6 |
Average Target Price | $22.80 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | 1.13 |